Investment Rating - The industry investment rating for the pharmaceutical and biotechnology sector is "Hold" [2]. Core Insights - The report highlights significant advancements in the field of metabolic disorders, particularly focusing on the PCSK9 target and small nucleic acid therapies, driven by the increasing prevalence of dyslipidemia in China, which now affects over 400 million people [5][7]. - Novartis' innovative cholesterol-lowering drug, Leqvio (inclisiran), has received approval for a new indication in China, aimed at treating adult patients with primary hypercholesterolemia or mixed dyslipidemia, enhancing treatment adherence and long-term management of LDL-C levels [5][6]. Summary by Sections Industry Overview - The report discusses the acceleration of resource integration and the rapid development of brain-computer interface technologies, indicating a shift towards innovative treatment paradigms in the medical field [4]. Market Dynamics - The number of patients with dyslipidemia in China has significantly increased, with a notable rise in cases of hypercholesterolemia, particularly among younger populations [6]. - The report notes that the global clinical development pipeline for PCSK9-targeted therapies includes 55 projects, with a focus on monoclonal antibodies and emerging small nucleic acid drugs [6]. Investment Recommendations - The report suggests investors pay attention to companies such as Heng Rui Medicine, Innovent Biologics, and East China Pharmaceutical, which are positioned to benefit from advancements in the metabolic disorder treatment landscape [7].

Core Viewpoint - Novartis has received approval from the National Medical Products Administration (NMPA) in China for its innovative small interfering RNA cholesterol-lowering drug, inclisiran, which is indicated as an adjunct to diet for adult patients with primary hypercholesterolemia (non-familial) or mixed dyslipidemia to lower low-density lipoprotein cholesterol (LDL-C) [1] Group 1 - Inclisiran is the first and currently the only approved small interfering RNA drug targeting PCSK9 for cholesterol reduction globally [1] - The approval expands the treatment options for patients with dyslipidemia, building on previous indications for use with statins or in combination with statins and other lipid-lowering therapies [1] - The biannual dosing regimen of inclisiran is expected to enhance treatment adherence and improve long-term LDL-C target achievement, aiding in the long-term management of lipid levels [1]

Core Viewpoint - Novartis announced the approval of its innovative cholesterol-lowering drug, Inclisiran (injectable), by the National Medical Products Administration of China, which will be used as an adjunct to diet for adults with primary hypercholesterolemia (non-familial) or mixed dyslipidemia to lower low-density lipoprotein cholesterol (LDL-C) [1] Group 1 - Inclisiran has received approval to expand its indications beyond previous approvals for use with statins or in combination with statins and other lipid-lowering therapies, thereby covering more patients with dyslipidemia [1] - As a targeted PCSK9 small interfering RNA cholesterol-lowering drug, Inclisiran's biannual dosing regimen is expected to enhance treatment adherence and improve long-term LDL-C target achievement rates, aiding in the long-term management of lipid levels [1]

Core Viewpoint - Novartis announced the approval of its innovative cholesterol-lowering drug, Leqvio (inclisiran sodium injection), by the National Medical Products Administration of China for use as an adjunct to diet in adults with primary hypercholesterolemia (non-familial) or mixed dyslipidemia to lower low-density lipoprotein cholesterol (LDL-C) [1] Group 1 - Novartis received approval for Leqvio from the Chinese regulatory authority [1] - The drug is indicated for adults with specific cholesterol-related conditions [1] - Leqvio is intended to be used alongside dietary measures [1]

Core Insights - Novartis has successfully included 2 new products and 4 new indications in the 2025 National Medical Insurance Drug List, including the world's first PCSK9 mRNA interference cholesterol-lowering drug, Leqvio (Inclisiran injection) [1][2] Group 1: Product Approval and Market Impact - Leqvio (Inclisiran injection) received approval from the National Medical Products Administration in August 2023 as an adjunct therapy for adults with primary hypercholesterolemia or mixed dyslipidemia [2] - The drug is indicated for patients who do not reach LDL-C targets despite maximum tolerated doses of statins, and can be used alone or in combination with other lipid-lowering therapies [2] - Since 1987, Novartis has had over 100 innovative drugs and new indications approved in China, with more than 40 drugs included in the National Medical Insurance Drug List since 2017 [2] Group 2: Cardiovascular Disease Context - Cardiovascular diseases are the leading cause of death among urban and rural residents in China, with 2 out of every 5 deaths attributed to these conditions [1] - The number of patients with cardiovascular diseases in China is estimated to be as high as 330 million, with a rising prevalence [1] - LDL-C levels are significantly correlated with the risk of atherosclerotic cardiovascular disease (ASCVD), with higher LDL-C levels indicating a greater risk over a 20-year period [1]